| 摘要 |
A pharmaceutical composition is provided to increase transcriptional activity of p53 and cell death by hindering analysis of p53 by MDM2 and to have anticancer effect suppressing dysplasia and carcinogenesis of cell. A pharmaceutical composition shows anticancer effect by including p19Ras protein as active component, uniting p19Ras protein with p53 protein and increasing activity of the p53 protein. The p19Ras protein is indicated as amino acid sequence of a sequence listing sequence number 1. The cancer is breast cancer, ovarian cancer, liver cancer, lung cancer, colon carcinoma or prostate cancer. An activity of the p53 protein is increased by hindering ubiquitination of p53 by MDM2.
|
